Researchers have developed an experimental blood test that could help detect pancreatic cancer at its earliest stages, potentially offering a new approach to identifying a disease that can often develop without noticeable symptoms.
The liquid biopsy, called PANXEON, was described in a study published in the journal Nature Medicine. Researchers said the test showed high sensitivity in detecting stage 1 and stage 2 pancreatic cancer, while maintaining a low rate of false-positive results.
The researchers also reported that PANXEON was able to identify high-grade dysplasia, a precancerous condition in the pancreas. Detecting such changes could potentially allow doctors to intervene before the condition progresses to invasive cancer.
Pancreatic cancer is often difficult to diagnose early because symptoms may not appear until the disease has advanced. Researchers said the findings highlight the potential of a blood-based approach for earlier detection.
However, PANXEON remains an experimental test and would require further validation and research before it could become part of routine clinical screening. The findings represent an early step towards developing less invasive methods for detecting pancreatic cancer at a stage when treatment options may be more effective.
